SMA, school and covid-19

On Friday evening TreatSMA hosted a webinar with Michelle Woods who is a SENDCo at a primary school in Kent. She has been a primary school teacher for 20 years and a SENDCo for 6 years.

Michelle currently works in a primary school with a Special Resourced Provision (SRP) for children with physical disabilities and complex medical needs and works hard to ensure that their needs are met in the school environment. Michelle works with children with a number of different needs and whilst is not an expert in SMA does support a child within the school with SMA.

Michelle kindly agreed to do a live webinar talking and answering questions about the school environment, covid and provisions that are and will need to be put in place for a child with SMA.

Michelle wanted to stress she is not an expert in SMA but is happy to share with others what lengths her school have gone to to make it as safe as possible for that child.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more